About wpteam

This author has not yet filled in any details.
So far wpteam has created 25 blog entries.

June 2021

Linnaeus Therapeutics Announces Expanded Clinical Collaboration with Merck to Include Multiple Additional Cohorts to Evaluate LNS8801 in Combination with KEYTRUDA® in Patients with Advanced Cancer

By |2021-06-16T10:15:45+00:00June 16th, 2021|

Linnaeus Therapeutics Announces Expanded Clinical Collaboration with Merck to Include Multiple Additional Cohorts to Evaluate LNS8801 in Combination with KEYTRUDA® in Patients with Advanced Cancer Studies Will be Conducted at Multiple NCI-Designated Comprehensive Cancer Centers Haddonfield NJ, June 15, 2021--Linnaeus Therapeutics, Inc. (Linnaeus), a privately held clinical-stage biopharmaceutical [...]

Linnaeus Therapeutics Announces Presentation of Positive Phase 1 Clinical Data of LNS8801 at 2021 ASCO Annual Meeting

By |2021-06-08T10:31:47+00:00June 8th, 2021|

Linnaeus Therapeutics Announces Presentation of Positive Phase 1 Clinical Data of LNS8801 at 2021 ASCO Annual Meeting Haddonfield NJ, June 7, 2021--Linnaeus Therapeutics, Inc. (Linnaeus), a privately held clinical-stage biopharmaceutical company focused on the development and commercialization of novel small-molecule oncology therapeutics, today announced the presentation of [...]

March 2021

Linnaeus Therapeutics Announces Issuance of Composition of Matter Patent for LNS8801 by the U.S. Patent and Trademark Office

By |2021-03-10T14:59:51+00:00March 10th, 2021|

Linnaeus Therapeutics Announces Issuance of Composition of Matter Patent for LNS8801 by the U.S. Patent and Trademark Office US Patent 10,934,277 Issued on March 2, 2021 Haddonfield NJ, March 10, 2021-- Linnaeus Therapeutics, Inc. (Linnaeus), a privately held clinical-stage biopharmaceutical company focused on the development and [...]

Linnaeus Therapeutics Granted Orphan Drug Designation for LNS8801 for the Treatment of Patients with Metastatic Uveal Melanoma

By |2021-03-10T14:50:51+00:00March 10th, 2021|

Linnaeus Therapeutics Granted Orphan Drug Designation for LNS8801 for the Treatment of Patients with Metastatic Uveal Melanoma Haddonfield NJ, March 10, 2021--Linnaeus Therapeutics, Inc. (Linnaeus), a privately held clinical-stage biopharmaceutical company focused on the development and commercialization of novel small-molecule oncology therapeutics, today announced that the U.S. [...]

October 2020

Linnaeus Therapeutics Announces First Patient Dosed in Its Clinical Trial of LNS8801 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Cancer

By |2020-10-16T14:58:12+00:00October 16th, 2020|

Company Commences Phase 2 Study at Multiple Academic Sites in United States Haddonfield NJ, October 13, 2020--Linnaeus Therapeutics, Inc. (Linnaeus), a privately held clinical-stage biopharmaceutical company focused on the development and commercialization of novel small molecule oncology therapeutics, today announced that it has dosed the first [...]

June 2020

Linnaeus Therapeutics Announces Clinical Trial Collaboration Agreement with Merck to Evaluate LNS8801 in Combination with KEYTRUDA in Patients with Advanced Cancer

By |2020-06-23T14:26:53+00:00June 23rd, 2020|

Linnaeus announced today announced that it has entered into a clinical collaboration agreement with Merck to evaluate the combination of its lead investigational product candidate LNS8801, and Merck’s anti-PD-1 therapy, KEYTRUDA®(pembrolizumab) in patients with selected advanced solid tumors. Haddonfield NJ, June 23, 2020--Linnaeus Therapeutics, Inc. (Linnaeus), a privately [...]

Linnaeus Therapeutics Granted U.S. FDA Fast Track Designation for LNS8801 for the Treatment of Patients with Metastatic or Unresectable Melanoma Who Have Progressed on Anti–PD-1/L1 Therapy

By |2020-06-22T14:22:50+00:00June 22nd, 2020|

Linnaeus Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for LNS8801 for the treatment of patients with metastatic or unresectable melanoma who have progressed on or after anti–programmed cell death receptor or ligand (anti–PD-1/L1) therapy. Haddonfield NJ, June 18, [...]

Linnaeus Therapeutics Scientific Cofounders Publish Preclinical Pancreatic Cancer Data in Cellular and Molecular Gastroenterology and Hepatology

By |2020-06-12T15:15:34+00:00June 10th, 2020|

Linnaeus Therapeutics Scientific Cofounders Publish Preclinical Pancreatic Cancer Data in Cellular and Molecular Gastroenterology and Hepatology Haddonfield NJ, June 10, 2020 -- Linnaeus Therapeutics, Inc. (Linnaeus), a privately held clinical-stage biopharmaceutical company focused on the development and commercialization of novel small molecule oncology therapeutics, today announced that its [...]

October 2019

Linnaeus Therapeutics Announces First Patient Dosed in Its Phase 1/2 Clinical Trial of LNS8801 in Patients with Advanced Cancer

By |2019-10-30T12:56:50+00:00October 30th, 2019|

Linnaeus Therapeutics Announces First Patient Dosed in Its Phase 1/2 Clinical Trial of LNS8801 in Patients with Advanced Cancer Company Commences First-in-Human Study at Multiple Academic Sites in United States Haddonfield NJ,October 29, 2019--Linnaeus Therapeutics, Inc. (Linnaeus), a privately held clinical-stage biopharmaceutical company focused on the development [...]

September 2019

Linnaeus Therapeutics Announces FDA Clearance of Investigational New Drug Application for LNS8801

By |2019-10-30T12:56:21+00:00September 24th, 2019|

Linnaeus Therapeutics Announces FDA Clearance of Investigational New Drug Application for LNS8801 Haddonfield NJ, September 24, 2019--Linnaeus Therapeutics, Inc. (Linnaeus), a privately held, clinical-stage biopharmaceutical company focused on the development and commercialization of novel, small molecule oncology therapeutics, today announced that the U.S. Food and Drug [...]